Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Federico Alberici"'
Autor:
Elena Oliva, Rosaria Santi, Lucio Manenti, Augusto Vaglio, Simeone Andrulli, Bruno Tumiati, Maria Letizia Urban, Alberto Pesci, Chiara Grasselli, Federica Maritati, Francesca Santarsia, Laura Pavone, Carlo Buzio, Alessandra Palmisano, Federico Alberici
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0185880 (2017)
PLoS ONE
PLoS ONE
Objectives The treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is based on remission-induction and remission-maintenance. Methotrexate is a widely used immunosuppressant but only a few studies explored its role fo
Autor:
Darren M. Roberts, Dinakantha S. Kumaratne, David Jayne, Stella Burns, Rachel B Jones, Federico Alberici, Rona M Smith
Publikováno v:
Journal of autoimmunity. 57
Rituximab is a B cell depleting monoclonal antibody used to treat lymphoma and autoimmune disease. Hypogammaglobulinemia has occurred after rituximab for lymphoma and rheumatoid arthritis but data are scarce for other autoimmune indications. This stu
Autor:
David Jayne, Federico Alberici
ANCA-associated vasculitis (AAV) is a subgrouping of autoimmune disorders characterized by a chronic relapsing course. Induction therapy is usually effective, but 70% of patients will relapse and 20% develop refractory disease. In the relapsing and r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8e3fc05ce220aa5ffe1a9e718625fc
http://hdl.handle.net/11379/527323
http://hdl.handle.net/11379/527323
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis
Autor:
Julia U Holle, Zdenka Hruskova, Oliver Flossmann, Vladimir Tesar, David Jayne, Federico Alberici, Kerstin Westman, Mark A. Little, Ravi Suppiah, Alessandra Palmisano, R N Batra, Augusto Vaglio, Chetan Mukhtyar, Raashid Luqmani, Bo Baslund, Coen A. Stegeman, Andrew Judge, Denise Brown
Publikováno v:
Rheumatology, 50(5), 899-905. Oxford University Press
OBJECTIVE: Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical checklist of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the BVAS version 3 (BVAS v. 3) in a cohor